91 results about "Vasospasm" patented technology

Systems and methods for assessing a physiological parameter of a target tissue wherein a pulse of focused ultrasound is applied to a target tissue site thereby inducing oscillation of the target tissue. By these systems and methods, a property of an acoustic signal emitted from the oscillating target tissue is measured and related to a physiological property of the tissue. Specific applications for systems and methods of the present invention include the assessment and monitoring of intracranial pressure (ICP), arterial blood pressure (ABP), CNS autoregulation status, vasospasm, stroke, local edema, infection and vasculitus, as well as diagnosis and monitoring of diseases and conditions that are characterized by physical changes in tissue properties.

The present invention relates to devices and systems that alter intracranial compliance, cerebral blood flow and / or intracranial pressure pulsatility / waveform by oscillating the contraction and expansion of a compressible composition within the cranial or spinal cavities such that they increase intracranial capacity. The contraction and expansion of the compressible composition in the oscillating compliance devices can be due to an individual's intracranial pressure, the result of the expansion and compression of a reservoir which is mediated by the contractility of the heart or driven by a pump gaited to a biorhythm. The invention also relates to methods for protecting an individual's brain from abnormal arterial pulsations and for altering an individual's cerebral blood flow using the devices and systems of the invention. The oscillating compliance devices can be used to treat several diseases and / or conditions characterized by altered / abnormal intracranial compliance, cerebral blood flow and / or intracranial pressure pulsatility / waveform, including hydrocephalus, stroke, dementia and migraine headaches, vasospasms, congestive heart failure, cardiopulmonary bypass or carotid endarterectomy.

Novel systems enable PTNA rapid exchange (RX) types of systems for ICAD, support balloon test occlusion, treatment of vasospasm after sub-arachnoid hemorrhage (SAH) and facilitate aneurysm neck remodeling during coiling embolization. The systems disclosed include an embodiment having a catheter comprising a RX port for providing catheter support within and above the carotid siphon and distal vertebral arteries, a conformable, semi-compliant balloon manipulable to gain forward progress through intracranial vessels substantially narrowed by plaque in combination with at least a guidewire, and a tip disposed at a distal end of the catheter.

The invention discloses a thrombus extraction support device. The thrombus extraction support device comprises a thrombus extraction support, a conveying guide wire, a guiding guide wire and marking rings, and is characterized in that the thrombus extraction support is composed of a front thrombus extraction support body and a back thrombus extraction support body; the marking rings include the middle-section marking ring and the near-end marking ring, the back end of the front thrombus extraction support body is fixedly connected with the back thrombus extraction support body through the middle-section marking ring, and the front end of the front thrombus extraction support body is fixedly connected with the guiding guide wire so that vascular irritation of the front thrombus extraction support body can be effectively reduced, and vasospasm in the thrombus extraction process can be prevented; the back end of the back thrombus extraction support body is fixedly connected with the near-end marking ring, the front end of the conveying guide wire is connected with the near-end marking ring, and the back end of the conveying guide wire is connected with a microtubule so that the front thrombus extraction support body and the back thrombus extraction support body can successively carry out thrombus extraction, and thrombus can be effectively prevented from falling in blood vessels. Due to the structure, the thrombus extraction support device has the advantages that the structure is simple, the capturing performance is high, thrombus extraction is complete, vasospasm is prevented, and the blood flow recovering velocity is high.

The invention relates to methods and products for treatment of hypertension, high blood pressure and vasospasm. Specifically, TRPC3 channel inhibitors and related compositions and kits are described.

A device and method for treatment of intracranial vasospasm is provided. The device is a microcatheter having a steeply tapered end and is thicker walled, and in a preferred embodiment is braided to provide greater pushability. In order to achieve a thicker walled catheter, in one embodiment, the inner lumen diameter can be reduced, leaving the outer diameter the same while in another embodiment the catheter is larger in outer diameter. In one embodiment, the microcatheter is coated with performance enhancing lubricant, such as a hydrophilic coating. Further, the microcatheter can also be coated with drugs and serve as a drug delivery device, drugs being embedded into vessel intima. In the use of the method of treatment, the device is fed into the smaller arterial vessels in the brain simultaneously dilating arteries of various caliber along the path of the catheter to relieve vasospasm; pharmacological agents can then be delivered by the microcatheter to further effect treatment.

The present invention relates to devices and systems that alter intracranial compliance, cerebral blood flow and / or intracranial pressure pulsatility / waveform by oscillating the contraction and expansion of a compressible composition within the cranial or spinal cavities such that they increase intracranial capacity. The contraction and expansion of the compressible composition in the oscillating compliance devices can be due to an individual's intracranial pressure, the result of the expansion and compression of a reservoir which is mediated by the contractility of the heart or driven by a pump gaited to a biorhythm. The invention also relates to methods for protecting an individual's brain from abnormal arterial pulsations and for altering an individual's cerebral blood flow using the devices and systems of the invention. The oscillating compliance devices can be used to treat several diseases and / or conditions characterized by altered / abnormal intracranial compliance, cerebral blood flow and / or intracranial pressure pulsatility / waveform, including hydrocephalus, stroke, dementia and migraine headaches, vasospasms, congestive heart failure, cardiopulmonary bypass or carotid endarterectomy.

The invention is directed to tricyclic benzodiazepines useful as vasopressin receptor antagonists for treating conditions involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising tricyclic benzodiazepines of the present invention and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.

The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration.

Cerebral Catheter devices and methods for use are provided. The catheter devices provided may include an anti-thrombotic agent coating on the exterior surface. The catheter devices may include unique tip configurations to allow improved fluid delivery capabilities. Further, the catheter devices may also or alternatively include one or more sensor devices in communication with a controller that allow automatically adjusting the delivery of a therapeutic fluid, for example a vasodilator, in response to the condition sensed by the catheter device, such as increased pressure. Moreover, the catheter devices may also be used in conjunction with blood flow transducers to detect and timely prevent and treatment vasospasms or other conditions. Methods for preventing and treatment vasospasm, neoplasm, or other pathological conditions while prolonged using the catheter device are also provided.

The invention belongs to the field of medicament technology, and especially relates to applications of a tetramethylpyrazine derivative tetramethylpyrazine nitrone to medicament preparation as well as prevention and treatment of brain injury diseases. Experiments prove that tetramethylpyrazine nitrone can improve traumatic brain injury and brain injury after subarachnoid hemorrhage; the improvements concretely comprise the following aspects: improvement of behaviors of model rats with traumatic brain injury and subarachnoid hemorrhage, reduction of cerebral infarction areas due to traumatic brain injury, improvement of vasospasm state after subarachnoid hemorrhage, and protection of brain tissues. Mechanisms of action of tetramethylpyrazine nitrone relate to inhibition of oxidative stress injuries, inhibition of inflammatory reactions, and apoptosis resistance. Tetramethylpyrazine nitrone can be used as a medicine for preventing and treating brain injury diseases, especially traumatic brain injury and subarachnoid hemorrhage, and can be prepared into various dosage forms with medicinal carriers.

Methods and compositions for preventing or reducing vascular smooth muscle contraction are provided. Exemplary compositions comprise an MLCK inhibitor, for example wortmannin, in an amount effective to prevent or reduce vascular smooth muscle vasospams by about 90% for at least about 20 minutes. Methods for identifying other modulators of MLCK are also provided.

Novel polymorphic forms of bosentan and processes for their preparation are disclosed. Further, pharmaceutical compositions comprising said polymorphic forms and the use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary hypertension, ischemia, vasospasm and angina pectoris are disclosed.

The invention relates to a N-aryl substituted-1H pyrrole derivative or its salt having cardiovascular activity represented by formula (I), which has activity angiotensin II (AII) acceptor antagonism and can be applied in treating cardiovascular diseases e.g. hypertension, hyperemia heart failure, myocardium pachismus, vasospasm and other diseases or symptoms treated through blockading AII acceptor.

The invention is directed to nonpeptide substituted benzodiazepines of Formula I, wherein A, X, n, R1, R2, R3, R4, R5, a and b are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.

Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.

Belonging to the field of traditional Chinese medicines, the invention discloses a drug for treatment of migraine. The drug provided by the invention comprises the following effective raw material components: Clerodendrum japonicum leaves, Parthenocissus tricuspidata, wild opium poppies, pomelo leaves, litmus, roots of Dentiferous Dendropanax, Cynanchum amplexicaule, Orixa japonica, crape myrtle roots, Astilbe chinensis, Piper longum, Hydrocotyle vulgaris, ergot, fructus viticis, radix clematidis and Korean Mondshood Roots. The drug provided by the invention has the efficacy of nourishing liver and dispelling wind, activating blood circulation and inducing resuscitation. Compared with other similar drugs, the drug provided by the invention has the characteristics of precise compatibility, mild drug properties and obvious curative effect, can rapidly ease migraine symptoms, dredge qi, blood and venations of lesions, promote vasodilatation, regulate the body mechanism, excite the inner analgesic system, relieve vasospasm, inhibit platelet aggregation and blood vessel substance release, thus curing diseases. The drug for treatment of migraine has the characteristics of good curative effect, quick effect, no toxic or side effect, convenient taking, easy absorption, low cost, treatment of both symptoms and root causes, and hard recurrence after cure.

The invention relates to a medicament for curing coronary heart diseases. The medicament is a preparation which comprises the following crude drugs by the weight part: 8 to 16 parts of Chinese angelica root, 9 to 19 parts of hoantchy root, 9 to 18 parts of ligusticum wallichii, 9 to 18 parts of red-rooted salvia root, 8 to 16 parts of Chinese thorowax root, 9 to 18 parts of glossy privet fruit, 9 to 18 parts of scrophulariaceae canaria, 9 to 18 parts of eucommia bark, 3 to 6 parts of aloe and 4 to 8 parts of antifebrile dichroa. The formula of the medicament focuses on the regulation of kidney functions, and at the same time, attaches importance to the coordination of functions of internal organs, such as the kidney, the heart, the liver, the spleen, etc. The medicament can not only reduce blood lipid, resist coagulation, reduce blood viscidity and dissolve internal clot, but also improve the functions of blood vessel endothelium. Furthermore, the medicament can remove vasospasm, resist arteriosclerosis and stabilize vulnerable plaque, and have double curative effects on blood diseases and vascular diseases, thereby effectively curing the cardiovascular system diseases.

Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.

The invention provides medicine for treating cardiovascular and cerebrovascular diseases. The medicine is glycoprotein, mixture of polysaccharide and protein, polypeptide or protein. The medicine has the advantages that the triglyceride and total cholesterol contents of rats can be lowered effectively; the anoxia survival time of mice can be prolonged to reach 70-85 minutes; the microcirculation can be improved, the coronary artery can be expanded, the myocardial blood supply can be improved, the blood flow of the brain and the coronary artery can be increased, the heart rate can be reduced, and the myocardial oxygen consumption index can be lowered to improve myocardial blood metabolism, resist thromboxane, increase high-density lipoprotein, resist vasospasm and reduce platelet aggregation, and the total cholesterol and triglyceride of the blood can be lowered; the medicine is safe, efficient and free of side effect.

The present invention relates to amino butanetriol aescin and its isomer for relieving swelling, diminishing inflammation and improving blood circulation. The amino butanetriol aescin is prepared with amino butanetriol and aescin, and has the structural formula as shown. The amino butanetriol aescin has high water solubility, lowered possibility of resulting in vasospasm and raised administrating safety.

The invention provides a method for establishing a coronary artery microvascular spasm pig-model, and belongs to the technical field of medical models. The method comprises that after bilateral femoral arteries of a test pig are free, distal ends of the femoral arteries are ligatured by wires, a left-side sheathing canal is fed into a pigtail catheter, blood flow dynamics indexes are determined, in a right-side sheathing canal, a coronary artery radiography process is carried out so that the middle of an anterior descending branch is displayed, and a neuropeptide Y is injected into the coronary artery so that the coronary artery microvascular spasm pig-model is obtained. The coronary artery microvascular spasm pig-model has good singularity, well fits to the clinical disease fact, satisfies clinical psychological stress characteristics, can be operated simply, is scientific and reasonable, has short modeling time, small damage and low animal mortality, realizes coronary artery microvascular evaluation on the carrier, realizes qualitative and quantitative evaluation of microvascular spasm state and degree, realizes real-time observation, provides a novel research means for basic clinical research and is suitable for popularization application.

A device and method for treatment of intracranial vasospasm is provided. The device is a microcatheter having a steeply tapered end and is thicker walled, and in a preferred embodiment is braided to provide greater pushability. In order to achieve a thicker walled catheter, in one embodiment, the inner lumen diameter can be reduced, leaving the outer diameter the same while in another embodiment the catheter is larger in outer diameter. In one embodiment, the microcatheter is coated with performance enhancing lubricant, such as a hydrophilic coating. Further, the microcatheter can also be coated with drugs and serve as a drug delivery device, drugs being embedded into vessel intima. In the use of the method of treatment, the device is fed into the smaller arterial vessels in the brain simultaneously dilating arteries of various caliber along the path of the catheter to relieve vasospasm; pharmacological agents can then be delivered by the microcatheter to further effect treatment.

Novel polymorphic forms of bosentan and processes for their preparation are disclosed. Further, pharmaceutical compositions comprising said polymorphic forms and the use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary hypertension, ischemia, vasospasm and angina pectoris are disclosed.

The invention discloses application of anisodine hydrobromide in preparing medicines for preventing or treating depression, in order to develop a medicine for effectively preventing or treating depression. Anisodine has the chemical formula of C17H21NO5 and a relative molecular weight of 319.35, is a pyrethroid type alkaloid, is present in belladonna plants and is a choline receptor blocking agent isolated firstly in China. The hydrobromide of the anisodine is mainly used clinically, and can be used for treating vascular headache, retinal vasospasm, central retinopathy, ischemic optic neuropathy, acute paralysis, paralysis agitans, bronchial asthma, kinesia, organic phosphorus pesticide poisoning and the like. However, literatures reporting treatment of depression are not available. In the invention, experiments show that anisodine hydrobromide plays a role in treating depression, and has a very good therapeutic effect in depression symptoms of interest blank, pleasant sensation disappearance, reduced exiting degree, reduced increment of body weight and the like.

The invention discloses a combined type micro vessel anastomat which comprises a circular ring, side columns, a sterilization film and a pressure sensor, wherein the side columns are movably connected to the periphery of the circular ring; the sterilization film is arranged at the periphery of the inner diameter of the circular ring; the pressure sensor is embedded to one end of the inner part of the circular ring. According to the combined type micro vessel anastomat, the situation that vessels are squeezed by external force can be prevented, and the vasospasm is avoided, so that vessels are kept smooth; besides, the endangium is kept to turn outwards to prevent vessel twist and keep vessel orifices stagger; moreover, secondary harm and pain of patients can be relieved by virtue of the circular ring made of an absorbing material.

This invention relates to methods and systems for providing a prognosis to a subject on developing vasospasm as a results of hemorrhagic event, and compounds and compositions for treatment thereof. Specifically, the invention relates to the use of haptoglobin genotyping in the prognosis of the development of vasospasm following SAH, and antioxidants such as glutathione peroxidase mimetics for treatment.

A therapeutic agent for subarachnoid hemorrhage or a drug for improving prognosis of subarachnoid hemorrhage, comprising a compound having a PAR1 inhibitory effect, its pharmaceutically acceptable salt or a hydrate thereof.

The invention discloses a hydraulic wrist developer. The hydraulic wrist developer comprises an elastic cavity, a signal control assembly arranged in the elastic cavity, and a force application mechanism used for switching on or off the signal control assembly. The signal control assembly controls switch-on and switch-off of a prompt signal. The force application mechanism comprises a hydraulic buffer, a reset spring and a stress support. According to the hydraulic wrist developer, light emitted by a vibrating light-emitting diode is adopted as the prompt signal, whether the grasping force of a blood donor is proper or not is visible, and the blood donor can timely adjust the force; the interval at which the reset spring drives a buffer rod of the hydraulic buffer to slowly retract is adopted as the frequency at which the blood donor grasps the wrist developer, thus, the blood donor can accurately apply force, vasospasm is avoided, and the blood drawing efficiency in a hospital is improved.